Literature DB >> 18005504

The incidence of pelvic inflammatory disease in untreated women infected with Chlamydia trachomatis: a structured review.

W L Risser1, J M H Risser.   

Abstract

Because of the long-term consequences of pelvic inflammatory disease (PID), the cost-effectiveness of Chlamydia trachomatis screening depends in part on the incidence of PID in untreated, chlamydia-infected women. The aim of this study was to evaluate the original research assessing the incidence of PID following C. trachomatis infection. We conducted a thorough search of the literature and selected all available prospective cohort studies. Six studies had original data: the incidence of PID varied from 0% (97.5% confidence interval [CI] 0-12%) during one year of follow-up of 30 women to 30% (95% CI 12-54%) during 50 days of follow-up of 20 women. Studies that included asymptomatic women in other settings reported a lower incidence than those that evaluated women in sexually transmitted disease clinics. In conclusion, no study was of a size or quality to answer our research question definitively. Investigators and clinicians planning chlamydia-screening programmes need to be cognizant of the inconclusive incidence data.

Entities:  

Mesh:

Year:  2007        PMID: 18005504     DOI: 10.1258/095646207782212351

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  9 in total

Review 1.  Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women.

Authors:  S Menon; P Timms; J A Allan; K Alexander; L Rombauts; P Horner; M Keltz; J Hocking; W M Huston
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 2.  Current knowledge of the aetiology of human tubal ectopic pregnancy.

Authors:  J L V Shaw; S K Dey; H O D Critchley; A W Horne
Journal:  Hum Reprod Update       Date:  2010-01-12       Impact factor: 15.610

3.  A pharmacy-based private chlamydia screening programme: results from the first 2 years of screening and treatment.

Authors:  Claire Anderson; Tracey Thornley
Journal:  Int J Clin Pharm       Date:  2011-01-13

4.  To develop and measure the effectiveness and acceptability of a pharmacy-based chlamydia screening intervention in Australia.

Authors:  Sajni Gudka; Lewis Marshall; Alison Creagh; Rhonda M Clifford
Journal:  BMJ Open       Date:  2013-08-17       Impact factor: 2.692

Review 5.  Intrauterine devices & infection: review of the literature.

Authors:  David Hubacher
Journal:  Indian J Med Res       Date:  2014-11       Impact factor: 2.375

Review 6.  Ectopic pregnancy secondary to in vitro fertilisation-embryo transfer: pathogenic mechanisms and management strategies.

Authors:  Bassem Refaat; Elizabeth Dalton; William L Ledger
Journal:  Reprod Biol Endocrinol       Date:  2015-04-12       Impact factor: 5.211

7.  Repeat infection with Chlamydia trachomatis: a prospective cohort study from an STI-clinic in Stockholm.

Authors:  Karin Edgardh; Sharon Kühlmann-Berenzon; Maria Grünewald; Maria Rotzen-Ostlund; Ivar Qvarnström; Jennie Everljung
Journal:  BMC Public Health       Date:  2009-06-22       Impact factor: 3.295

Review 8.  T cell responses to Chlamydia.

Authors:  Jennifer D Helble; Michael N Starnbach
Journal:  Pathog Dis       Date:  2021-03-31       Impact factor: 3.166

9.  Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model.

Authors:  Malcolm J Price; A E Ades; Daniela De Angelis; Nicky J Welton; John Macleod; Kate Soldan; Ian Simms; Katy Turner; Paddy J Horner
Journal:  Am J Epidemiol       Date:  2013-06-27       Impact factor: 4.897

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.